ClinicalTrials.gg
RecruitingNCT07098403Updated Sep 9, 2025

A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma

A Phase 3 interventional study of SHR-1905 Injection and SHR-1905 Placebo Injection in Asthma, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd. — 5 open to participants now, 6 under way, 2 of them phase 3. Asthma · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
Largest of 15
408 · median 84
Started
2025
with 3 others
Phase 3
2 of 15
1 open now
Registered
14th of 15
by date

Among the 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd., this one has the largest planned enrollment, is one of 4 that started in 2025, is one of 2 in phase 3, and was the 14th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

5 of the 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This study is a phase III study of SHR-1905 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of SHR-1905 in subjects with severe uncontrolled asthma.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18.
  2. Documented physician-diagnosed asthma for at least 12 months.
  3. Participants who have received asthma controller medication with medium or high dose ICS for at least 6 months.
  4. Documented treatment with a total daily dose of either medium or high dose ICS (Refer to Guidelines for the prevention and management of bronchial asthma (2024 edition)) for at least 3 months.
  5. At least one additional maintenance asthma controller medication is required according to standard practice of care and must be documented for at least 3 months.
  6. Pre-BD \< 80% predicted normal.
  7. Objective evidence of asthma as documented.
  8. Documented history of at least 2 asthma exacerbation events within 12 months, and at least one of the exacerbations should occur during the treatment of medium-to-high dose ICS.
  9. ACQ-6 score ≥ 1.5 at screening and on day of baseline.
  10. ePRO adherence ≥ 70% in the 7 days prior to randomization.

Exclusion criteria

Exclusion Criteria:

  1. pulmonary disease other than asthma.
  2. History of cancer.
  3. History of a clinically significant infection.
  4. Current smokers or participants with smoking history ≥ 10 pack-yrs.
  5. History of chronic alcohol or drug abuse within 12 months.
  6. , C or .
  7. Pregnant or breastfeeding.
  8. History of anaphylaxis following any biologic therapy.
  9. participant randomized in the current study or previous SHR-1905 studies.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
408 participants (estimated)

Study arms

  • Experimental
    SHR-1905 Group

    Drug: SHR-1905 Injection

  • Placebo comparator
    SHR-1905 Placebo Group

    Drug: SHR-1905 Placebo Injection

Interventions

  • SHR-1905 injection.

  • DrugSHR-1905 Placebo Injection

    SHR-1905 placebo Injection.

06

What researchers measure

Primary outcomes

  1. Annual asthma exacerbation rate

    Time frame: During 48 weeks of treatment.

Secondary outcomes

  1. Mean change from baseline in pre-dose/pre-bronchodilator (Pre-BD) forced expiratory volume in 1 Second (FEV1)

    Time frame: At Week 48.

  2. Proportion of participants who had asthma exacerbations

    Time frame: From randomization to Week 48.

  3. Time to the first asthma exacerbation

    Time frame: From randomization to Week 48.

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510830, China
    Recruiting
    • Nanshan Zhong · Contactnanshan@vip.163.com · +86-020-83062893
    • Xinyan Yang · Contacticeyxy@126.com · +86-020-81567196
    • Nanshan Zhong · Principal investigator
    • Xinyan Yang · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jan 2028, 28 months after the start.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 28 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2025
First posted
Aug 1, 2025
StartActual
Sep 3, 2025
Primary completionEst.
Jan 2028
CompletionEst.
Jun 2028
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07098403
Responsible party
Sponsor
First posted
Aug 1, 2025
Start date
Sep 3, 2025
Primary completion
Jan 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Sep 9, 2025

Study contacts

Zhou Li
Contact
zhou.li.zl69@hengrui.com
+86-020-62726806

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1905

Start the discussion